NCT07054034

Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects

A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of MG-ZG122 Humanized Monoclonal Antibody Injection in Adult Subjects With Moderate-to-Severe Asthma to Evaluate Efficacy and Safety

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 160 (estimated)
• Sponsor: Shanghai Mabgeek Biotech.Co.Ltd · Industry
• Sex: All
• Age: 15 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of MG-ZG122 Humanized Monoclonal Antibody Injection in Asthma Subjects, with Dosing Every 12 or 24 Weeks for 48 Weeks

Detailed description

This study is a multicenter, randomized, double-blind, placebo-controlled Phase II study. Approximately 160 adult asthma subjects are scheduled to receive multiple subcutaneous injections (every 12 or 24 weeks for 48 weeks). The study is divided into a screening period (1 week), a run-in period (4 weeks), a treatment period (48 weeks), and a follow-up period (12 weeks).

Conditions

• Bronchial Asthma

Interventions

Type	Name	Description
DRUG	MG-ZG122 Humanized Monoclonal Antibody Injection	MG-ZG122 Humanized Monoclonal Antibody Injection
OTHER	Placebo	MG-ZG122 Humanized Monoclonal Antibody Injection Placebo

Timeline

• Start date: 2025-05-11
• Primary completion: 2026-05-26
• Completion: 2027-05-26
• First posted: 2025-07-08
• Last updated: 2025-07-08

Locations

1 site across 1 country: China